- Home
- IPSC vs NCSM Comparison
IPSC vs NCSM Comparison
Compare IPSC & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- NCSM
- Stock Information
- Founded
- IPSC 2019
- NCSM 2006
- Country
- IPSC United States
- NCSM United States
- Employees
- IPSC N/A
- NCSM N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- NCSM Oilfield Services/Equipment
- Sector
- IPSC Health Care
- NCSM Energy
- Exchange
- IPSC Nasdaq
- NCSM Nasdaq
- Market Cap
- IPSC 77.3M
- NCSM 68.4M
- IPO Year
- IPSC 2021
- NCSM 2017
- Fundamental
- Price
- IPSC $0.89
- NCSM $29.92
- Analyst Decision
- IPSC Strong Buy
- NCSM
- Analyst Count
- IPSC 4
- NCSM 0
- Target Price
- IPSC $11.00
- NCSM N/A
- AVG Volume (30 Days)
- IPSC 562.3K
- NCSM 10.4K
- Earning Date
- IPSC 03-13-2025
- NCSM 03-06-2025
- Dividend Yield
- IPSC N/A
- NCSM N/A
- EPS Growth
- IPSC N/A
- NCSM N/A
- EPS
- IPSC N/A
- NCSM 16.77
- Revenue
- IPSC $2,684,000.00
- NCSM $152,801,000.00
- Revenue This Year
- IPSC $230.51
- NCSM $13.26
- Revenue Next Year
- IPSC $31.87
- NCSM $6.32
- P/E Ratio
- IPSC N/A
- NCSM $1.77
- Revenue Growth
- IPSC 7.88
- NCSM 3.66
- 52 Week Low
- IPSC $0.87
- NCSM $14.73
- 52 Week High
- IPSC $5.51
- NCSM $30.44
- Technical
- Relative Strength Index (RSI)
- IPSC 33.61
- NCSM 65.65
- Support Level
- IPSC $0.87
- NCSM $27.10
- Resistance Level
- IPSC $0.95
- NCSM $29.67
- Average True Range (ATR)
- IPSC 0.09
- NCSM 1.17
- MACD
- IPSC -0.00
- NCSM 0.12
- Stochastic Oscillator
- IPSC 11.39
- NCSM 90.61
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc provides products and support services that facilitate the optimization of oil and natural gas well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's primary offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. Geographically, majority of revenue is generated from United States.